Benelux Morning Notes

Alfen: Preview - muddling through? Belgian telcos: Competition Authority investigation on Proximus/Orange Belgium MoU. Brunel International: 2Q25 below, 3Q25 outlook cut, cost savings protect FY25 estimates. Euronext: Another record set of results. Fugro: Sharper V-shape? GBL: Weak NAV performance, as expected. KBC Ancora: Cooperative CERA increasing its stake to 51.24%, using excess cash. UCB: Renewed US threats to cut drug prices. Umicore: 1H25 and guide broadly in-line, new S...

Morning Notes : BFITa NA, ELI BB, ALFEN NA, TKWYa NA

: BFITa NA, ELI BB, ALFEN NA, TKWYa NA

Alfen: new CEO to join in October

Yesterday, Alfen announced the appointment of Michael Colijn as CEO and chairman of the management board. This comes after Marco Roeleveld, former CEO and a key figure of Alfen since 1997, who led the IPO in 2018, announced he would retire by year-end for medical reasons. The appointment of Michael

MaaT Pharma Secures € 37.5m tranched EIB financing

MaaT announced that it has secured a € 37.5m , 4-tranche financing from the European Investment Bank (EIB), which bears interest at 7%. In addition, MaaT will issue warrants to the EIB with each tranche. MaaT's previously communicated cash runway was into January 2026, which should now extend beyond that point following this additional funding, though we do note that disbursement of Tranches B to D is subject to operational and financing conditions, which we'd be keen to learn more about. All in...

Morning Notes : AALB NA, HNK1 NA, HKHHF NA, RETb BB, AZEb BB, MATPF FP

: AALB NA, HNK1 NA, HKHHF NA, RETb BB, AZEb BB, MATPF FP

Morning Notes : AED BB, AKZA NA, MAAT FP

: AED BB, AKZA NA, MAAT FP

MaaT Pharma Partnership with Clinigen secures MaaT013's EU commerciali...

MaaT signed a licensing, distribution, and commercial supply agreement with Clinigen in Europe for Xervyteg (MaaT013, microbiome therapy, enema formulation) in aGvHD for a € 10.5m upfront, € 18m in milestones, and mid-thirties flat royalty on sales. We believe this deal serves as validation of MaaT013's potential, and see the partnership as a de-risking event for MaaT013's commercialisation in Europe, given Clinigen's experience commercialising in haemato-oncology, with 3 products currently on t...

ODDO BHF SECURITIES Small & MIDCAP MORNING NEWS – 07/02/2025

ODDO BHF SECURITIES Small & MIDCAP MORNING NEWS – 02/07/2025

Alfen : CEO to retire for health reasons

Benelux Morning Notes

Alfen: CEO intends to retire early. D'Ieteren: Belgian June car registrations down 16%, VW down only 5%, good mix. Euronext: Bearing gifts to Greeks. JDE Peet's: Instant Decaf

Morning Notes : MELE BB, TINC BB, VGPb BB, ALFEN NA, ARGp FP, JDEP NA

: MELE BB, TINC BB, VGPb BB, ALFEN NA, ARGp FP, JDEP NA

Alfen: CEO Marco Roeleveld to retire early

Yesterday, Alfen announced that CEO Marco Roeleveld will retire by year-end for medical reasons. Marco Roeleveld has been a key figure since 1997 and led Alfen’s IPO in 2018. The board has begun the search for his successor. This announcement comes after CCO Michelle Lesh stepped down in March 2025

Alfen Early retirement CEO

Alfen announced last evening that its CEO, Marco Roeleveld, will retire by the end of the year due to health reasons. Roeleveld, who led Alfen through its 2018 IPO and significant growth, emphasized that the decision, though difficult, is necessary to focus on his recovery. The Supervisory Board has initiated the search for a successor and expressed confidence in a smooth leadership transition. Alfen enters a transition phase where the appointment of a new CEO and the definition of a refreshed s...

Morning Notes : VPK NA, MAAT FP, ZEAL DC

: VPK NA, MAAT FP, ZEAL DC

MaaT Pharma Business update highlights upcoming priorities, final ARES...

MaaT provides a business update, which reiterated the company's progress with respect to its pipeline, and following the previously announced EU regulatory submission for MaaT013 in aGvHD, the company continues to search for a commercialisation partner in Europe ahead of a potential approval in 2H26. Timeline for MaaT013 US trial launch shifts to 2026 (from 4Q25) to focus resources on the European opportunity. Looking ahead, data updates for MaaT013 in aGvHD (final results incl. 12-month OS), as...

Utilities and offshore wind supply chain sector/Mind the gaps

In this report we present our view on the long-term growth prospects for offshore wind in Europe, implications of the energy transition and the role of TSOs, such as Elia Group. We also focus on supply chain beneficiaries in our Benelux coverage. An increasing number of long-term framework contracts should provide improved risk-rewards to the supply chain, in our view. Furthermore, we take a deep dive into growth drivers and long-term financing for Elia Group, beyond the company's current financ...

MaaT Pharma Updated MaaT013 aGvHD EAP data at EHA shows consistent out...

MaaT reported updated early access program (EAP) results for MaaT013 (microbiome therapy, enema formulation) in aGvHD at EHA, being held 12-15 June. The data, which was previously shared in the abstract last month, shows that the response rates and overall survival observed in the steroid refractory and ruxulitinib resistant subset of patients (n=70) are in line with what was observed in the phase 3 ARES trial. In our view, this points to the consistency of outcomes with MaaT013 in this patient ...

Morning Notes : AGFB BB, BPOST BB, GLPG NA, PROX BB, UCB BB, MAAT FP

: AGFB BB, BPOST BB, GLPG NA, PROX BB, UCB BB, MAAT FP

MaaT Pharma Completes EU regulatory submission for MaaT013 in aGvHD

MaaT announced the submission of the Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its lead drug candidate MaaT013 (microbiome therapy, enema formulation) in aGvHD under the brand name Xervyteg. Potential approval could be granted in 2H26, and MaaT is actively exploring strategic partnerships to commercialise MaaT013 in Europe. We believe the solid phase 3 results and good uptake in the early access program will be supportive of MaaT013's commercial launch ...